In this podcast, expert clinicians compare the immunogenicity of available biologic therapies and explore options for managing patients who develop anti-drug antibodies. 

MedEdTalks - Gastroenterology

Immunogenicity of Current IBD Biologics With Drs. Edward Loftus and Marla Dubinsky

In this podcast, expert clinicians review the variety of extraintestinal manifestations seen in patients with IBD, discussing strategies for assessment and management.

Extraintestinal Manifestations of IBD With Drs. Edward Loftus and Miguel Regueiro

In this podcast, experts review appropriate applications of monotherapy and combination therapy and how to position particular therapies based on disease and patient characteristics. 

Biologics for IBD – Monotherapy Versus Combination Approaches With Drs. Edward Loftus and Marla Dubinsky

In this podcast, expert clinicians will discuss the shift from symptom-based management to a treat-to-target paradigm, detailing important treatment aims and reviewing the mechanisms of action of available therapies. 

New Insights on Treat to Target in Moderate to Severe IBD With Drs. Edward Loftus and Miguel Regueiro

In this podcast, expert clinicians will discuss new evidence on investigational agents, the anti-IL-23 and JAK inhibitors, that are in late-stage development for treating moderate to severe CD.

Efficacy and Safety of Anti-interleukin (IL) 23 and Janus Kinase (JAK) Inhibitors with Drs. William J. Sandborn and Jessica R. Allegretti

In this podcast, expert clinicians will discuss new evidence on investigational agents, the anti-integrin and S1P-1 receptor modulators, that are in late-stage development for treating moderate to severe CD.

Efficacy and Safety of Anti-integrin and Sphingosine-1-Phosphate (S1P)-1 Receptor Modulators with Drs. Bruce E. Sands and William J. Sandborn

In this podcast, expert clinicians will discuss emerging therapies with unique mechanisms of action that can improve the treatment of moderate to severe Crohn’s disease.

Mechanisms of Action of New Classes of Agents for Moderate to Severe Crohn’s Disease with Drs. William J. Sandborn and Bruce E. Sands

Investigational Agents in Ulcerative Colitis: IL-12 and IL-23 InhibitorsInflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patients still suffer poor quality of life and suboptimal outcomes. Therefore, safer and more effective UC therapies are needed. In this CME podcast activity, Dr. Peter Higgins and Dr. David Rubin will discuss investigational interleukin-12 and interleukin-23 inhibitors for treating UC. For the transcript of this podcast, click here. To obtain CME credit, click here

Investigational Agents in Ulcerative Colitis: IL-12 and IL-23 Inhibitors

Inflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patients still suffer poor quality of life and suboptimal outcomes. Therefore, safer and more effective UC therapies are needed. In this CME podcast activity, Dr. Peter Higgins and Dr. William Sandborn will discuss investigational Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators for treating UC. For the transcript of this podcast, click here. To obtain CME credit, click here

Investigational Agents in Ulcerative Colitis: JAK Inhibitors and S1P Receptor Modulators

Inflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patients still suffer poor quality of life and suboptimal outcomes. Therefore, safer and more effective UC therapies are needed. In this CME podcast activity, Dr. David Rubin and Dr. Peter Higgins will discuss investigational anti-integrin therapies for UC. For the transcript of this podcast, click here To obtain CME credit, click here

Investigational Agents in Ulcerative Colitis: Anti-Integrins

Inflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patients still suffer poor quality of life and suboptimal outcomes. Therefore, safer and more effective UC therapies are needed. In this CME podcast activity, expert physicians will discuss investigational UC therapies with various mechanisms of action. For the full CME activity, click here

Ulcerative Colitis: Targeting Immunological Pathways in Moderate to Severe Disease – Updates From Copenhagen

MedEdTalks Gastroenterology is a continuing medical education podcast for physicians to allow them to learn while on the go and obtain CME credits. This show will focus in on gastroenterology topics, such as ulcerative colitis (UC) and Crohn’s disease and includes interviews with Dr. Peter Higgins from the University of Michigan, Dr. David Rubin from the University of Chicago and Dr. William Sandborn from the University of California, San Diego.

hubhopper

MedEdTalks - Gastroenterology

hubhopper